EURO-EWING-99-R2

NCT00020566 📎

Regimen

Experimental
High-dose busulfan-melphalan + autologous stem cell rescue
Control
Conventional VAI consolidation

Population

High-risk localized Ewing (poor histologic response post-induction, or large axial tumor)

Key finding

BuMel + auto-HSCT improved EFS by ~14 percentage points in high-risk localized Ewing. One of few modern positive bone-sarcoma intensification RCTs. European standard for this subset.

Source: PMID 30188789

Timeline

    Guideline citations

    • NCCN BONE (p.33)